A second chance for hormone replacement therapy

EMBO Reports

Volumn 4, Issue 12, 2003, Pages 1112-1115

  Brower, Vicki ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TESTOSTERONE; THALIDOMIDE;

ALZHEIMER DISEASE; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COLON CANCER; DEMENTIA; DISEASE PREDISPOSITION; DRUG EFFICACY; FEMALE; HEART PROTECTION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LIBIDO DISORDER; MALE; MENOPAUSAL SYNDROME; MUSCLE DISEASE; NEUROLOGIC DISEASE; NEUROPROTECTION; OSTEOPOROSIS; OVARY CANCER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS;

AGING; ARTERIOSCLEROSIS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CHEMISTRY, PHARMACEUTICAL; ESTROGENS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; NERVOUS SYSTEM DISEASES; PRACTICE GUIDELINES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE;

EID: 0346463138     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.embor.7400043     Document Type: Article

References (12)

1. Anderson, G.L., Judd, H.L., Kaunitz, A.M., Barad, D.H., Beresford, S.A.A., Pettinger, M., Liu, J., McNeeley, S.G. & Lopez, A.M. (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA, 290, 1739-1748.
2. Cauley, J.A. et al. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA, 290, 1729-1738.
3. Grodstein, F. & Stampfer, M.J. (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New Engl. J. Med., 335, 453-462.
4. Lawton, B., Rose, S., McLeod, D. & Dowell, A. (2003) Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of users. Br. Med. J., 327, 845-846.
5. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362,419-427.
6. Nilsen, J. & Brinton, R.D. (2002a) Impact of progestins on oestradiol potentiation of the glutamate calcium response. Neuroreport, 13, 825-830.
7. Nilsen, J. & Brinton, R.D. (2002b) Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology, 143,205-212.
8. Nilsen, J. & Brinton, R.D. (2003) Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl Acad. Sci. USA, 100, 10506-10511.
9. Rapp, S.R. et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative memory study: a randomized controlled trial. JAMA, 289, 2663-2672.
10. Shumaker, S.A. et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289, 2651-2662.
11. Wassertheil-Smoller, S. et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA, 289, 2673-2684.
12. Zandi, P.P., Carlson, M.C., Plassman, B.L., Welsh-Bohmer, K.A., Mayer, L.S., Steffens, D.C. & Breitner, J.C. (Cache County Memory Study Investigators) (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA, 288, 2123-2129.